Flow diverters (FDs), as an addition to the endovascular treatment options for intracranial aneurysms, have higher surface coverage and lower porosity than conventional intracranial stents. Their design focuses on diverting flow from the aneurysm, thus creating an environment prone to thrombosis. FDs may also provide scaffolding for endothelialization and vessel wall healing. Treatment of complex anterior circulation aneurysms, predominantly internal carotid artery (ICA) aneurysms, with FDs has become common practice in neurovascular centers \[[@CR1]--[@CR3]\]. However, flow diverter treatment for posterior circulation aneurysms (PCAs) still remains controversial because of significantly higher rates of ischemic stroke and perforator infarction than those observed for anterior circulation aneurysms \[[@CR1]--[@CR4]\].

In recent years, several studies have reported on the safety and efficacy of flow diverter treatment for PCAs \[[@CR1]--[@CR3], [@CR5]--[@CR15]\], but none have systematically evaluated the rate of mortality, aneurysmal occlusion, and procedure-related complications. It is therefore the aim of this systematic review and meta-analysis to provide a systematic understanding of the flow diverter treatment for PCAs, which would help guide practitioners in selecting the best therapy method for patients with complex PCAs.

Methods {#Sec1}
=======

We conducted PubMed, OVID, and Web of Science searches to review all studies on the treatment of PCAs with FDs. In brief, we used the keywords "Posterior Circulation Aneurysms," "PED," "pipeline embolization device," "flow diverter," "divert," "diversion," and "pipeline." Inclusion criteria were as follows: English language, ≥5 patients, studies published between July 2005 and July 2015, and the presence of data on procedure-related good outcome or mortality or aneurysmal occlusion rate or postoperative complications. The exclusion criteria were as follows: case reports, in vitro or cadaveric studies, review articles, guidelines, technical notes, and whether only a subset of patients of the total number of patients treated with FDs was analyzed. We also searched the reference lists of all eligible studies and pertinent publications for additional studies.

In the case of overlapping study populations, we tried to exclude the possibility of individual patients being described twice. When patients were included in multiple studies, we contacted the study authors by e-mail to exclude the duplicate cases. If the repetitive data could not be definitively sorted out, the report with the higher number of patients and/or the longer follow-up was selected \[[@CR16]\]. Abstracts, methods, results, figures, and tables of the full studies were searched for data on procedure-related good outcome and mortality, aneurysmal occlusion rates, and postoperative complications.

Epidemiological data included the number of patients and aneurysms, the features of the aneurysms as well as the clinical presentation (incidental, hemorrhagic, or symptomatic) of the patients. Aneurysms were classified as small (\<10 mm), large (10 mm ≤ aneurysm size ≤ 25 mm), or giant (\>25 mm). The shape of aneurysms was classified as saccular and not saccular. The state of aneurysms was divided into ruptured and unruptured, herein ruptured aneurysms referred to the ones received flow diverter treatment in the acute stage. The term good outcome was defined as modified Rankin scale of 0--2 (mRS 0--2) and mortality as mRS 6. Aneurysmal occlusion was defined as complete occlusion at 6-month digital subtraction angiography (DSA). Postoperative complications were analyzed with respect to ischemic stroke, perforator infarction, subarachnoid hemorrhage (SAH), and intraparenchymal hemorrhage (IPH). Subgroup analysis was conducted between study outcomes and the characteristics of aneurysms and patients.

Statistical analyses {#Sec2}
--------------------

Random-effect meta-analysis was performed on studies that provided data on outcomes of patients who underwent flow diverter treatment. We estimated from each study the cumulative incidence (event rate) and 95 % CI for each outcome. Subgroup analysis was carried out to evaluate the impact of the preoperative conditions on the results, which was presented as odds ratios (OR) with a 95 % CI. Statistical heterogeneity across studies was assessed using the *I*^2^ statistic. We evaluated potential publication bias by using funnel plots.

Results {#Sec3}
=======

Study selection {#Sec4}
---------------

Our search strategy revealed a total number of 171 different studies, 143 of which were excluded by title and abstract screening. Of the 28 remaining studies, full texts were accessed, and ten studies met our predefined inclusion criteria. Two additional studies were found by considering the reference lists of the ten previously mentioned studies, and another two additional studies were found from pertinent publications. As a result, a total of 14 studies were included in the analysis (Table [1](#Tab1){ref-type="table"}), including seven prospective single-arm cohort studies and seven retrospective case series. Figure [1](#Fig1){ref-type="fig"} presents a flow chart illustrating the above search process.Table 1Studies included in meta-analysisAuthorTitleJournalYearStudy designNo. of patientsAneurysms treatedByrne, J.V. et al. \[[@CR5]\]Early experience in the treatment of intracranial aneurysms by endovascular flow diversion: a multicenter prospective studyPLoS ONE2010Prospective2020Kulcsar, Z. et al. \[[@CR9]\]High-profile flow diverter (silk) implantation in the basilar artery: efficacy in the treatment of aneurysms and the role of the perforatorsStroke2010Retrospective1212Chalouhi, N. et al. \[[@CR3]\]Treatment of posterior circulation aneurysms with the pipeline embolization deviceNeurosurgery2013retrospective77Siddiqui, A.H. et al. \[[@CR12]\]Panacea or problem: flow diverters in the treatment of symptomatic large or giant fusiform vertebrobasilar aneurysmsNeurosurgery2012Prospective77Toth, G. et al. \[[@CR14]\]Posterior circulation flow diversion: a single-center experience and literature reviewJournal of Neurointerventional Surgery2015Retrospective67Meckel, S. et al. \[[@CR7]\]Endovascular treatment of complex aneurysms at the vertebrobasilar junction with flow-diverting stents: initial experienceNeurosurgery2013Retrospective77Toma, A.K. et al. \[[@CR6]\]Early single centre experience of flow diverting stents for the treatment of cerebral aneurysmsBritish Journal of Neurosurgery2013Prospective1717Monteith, S.J. et al. \[[@CR8]\]Endovascular treatment of fusiform cerebral aneurysms with the pipeline embolization deviceNeurosurgery2014Retrospective77Phillips, T.J. et al. \[[@CR2]\]Safety of the pipeline embolization device in treatment of posterior circulation aneurysmsAmerican Journal of Neuroradiology2012Prospective3232Munich, S.A., et al. \[[@CR13]\]The pipeline embolization device for the treatment of posterior circulation fusiform aneurysms: lessons learned at a single institutionNeurosurgery2014retrospective1212McAuliffe, W. et al. \[[@CR10]\]Immediate and midterm results following treatment of recently ruptured intracranial aneurysms with the pipeline embolization deviceAmerican Journal of Neuroradiology2012Prospective66De Vries, J. et al. \[[@CR11]\]New generation of Flow Diverter (surpass) for unruptured intracranial aneurysms: a prospective single-center study in 37 patientsStroke2013Prospective55Kallmes, D.F. et al. \[[@CR1]\]International retrospective study of the pipeline embolization device: a multicenter aneurysm treatment studyAmerican Journal of Neuroradiology2015Retrospective5559Wakhloo, A.K. et al. \[[@CR15]\]Surpass flow diverter in the treatment of intracranial aneurysms: a prospective multicenter studyAmerican Journal of Neuroradiology2015Prospective2727Fig. 1Selection of included studies

Aneurysm and patient characteristics {#Sec5}
------------------------------------

A total of 220 patients with 225 PCAs (16 % \[*n* = 25, 95 % CI 10--22\] ruptured, 84 % \[*n* = 136, 95 % CI 78--90\] unruptured) were included in the analyses. In terms of size, 29 % of the aneurysms were classed as small (*n* = 48, 95 % CI 22--37), 48 % (*n* = 79, 95 % CI 40--56) were classed as large, and 23 % (*n* = 38, 95 % CI 17--30) were giant aneurysms. Thirty-four percent (*n* = 58, 95 % CI 27--42) were saccular aneurysms, and 66 % (*n* = 111, 95 % CI 58--73) were not; 26 % (*n* = 27, 95 % CI 18--36) of the patients with aneurysms received FD treatment as a retreatment. Of the 220 patients, 61 % (*n* = 62, 95 % CI 51--70) were symptomatic, and the other 39 % (*n* = 40, 95 % CI 30--49) were asymptomatic (Table [2](#Tab2){ref-type="table"}). The location distribution of the aneurysms was showed in Fig. [2](#Fig2){ref-type="fig"}.Table 2Characteristics of aneurysms and patientsRate95 % CI*N*Posterior circulation aneurysm Small0.290.22--0.3748 Large0.480.40--0.5679 Giant0.230.17--0.3038 Saccular0.340.27--0.4258 Not saccular0.660.58--0.73111 Ruptured0.160.10--0.2225 Unruptured0.840.78--0.90136 Retreatment0.260.18--0.3627 First treatment0.740.64--0.8275Patient Symptomatic0.610.51--0.7062 Asymptomatic0.390.3--0.4940*CI* confidence interval, *N* numberFig. 2The location distribution of the aneurysms. *BA* basilar artery, *SCA* superior cerebellar artery, *AICA* anterior inferior cerebellar artery, *PICA* posterior inferior cerebellar artery, *VA* vertebral artery, *VB* vertebrobasilar junction, *PCA* posterior cerebral artery

Study outcomes {#Sec6}
--------------

Procedure-related good outcome rate was 79 % (95 % CI 72--84), with significantly lower rates among patients with ruptured aneurysms and basilar artery aneurysms (OR 0.22, 95 % CI 0.06--0.82 and OR 0.14, 95 % CI 0.04--0.54, respectively; Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). Aneurysm size, aneurysm type, preoperative symptoms, and prior treatment were not significantly associated with the rate of procedure-related good outcome (OR 0.99, 95 % CI 0.37--2.66; OR 6.20, 95 % CI 0.69--55.55; OR 0.20, 95 % CI 0.04--1.07; and OR 1.72, 95 % CI 0.40--7.34, respectively).Fig. 3Forest plot and meta-analysis of procedure-related good outcome rate: ruptured aneurysms vs. unruptured aneurysms. *M-H* Mantel-Haenszel method, *CI* confidence intervalFig. 4Forest plot and meta-analysis of procedure-related good outcome rate: basilar artery aneurysms vs. non basilar artery aneurysms. *M-H* Mantel-Haenszel method, *CI* confidence interval

Procedure-related mortality rate was 15 % (95 % CI 10--21), with significantly higher rates among patients with giant aneurysms and basilar artery aneurysms (OR 3.77, 95 % CI 1.35--10.54 and OR 4.65, 95 % CI 1.24--17.40, respectively; Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}). Aneurysm state, aneurysm type, preoperative symptoms, and prior treatment were not significantly associated with the rate of procedure-related mortality (OR 1.96, 95 % CI 0.28--13.62; OR 0.15, 95 % CI 0.02--1.13; OR 2.17, 95 % CI 0.17--27.91; and OR 0.33, 95 % CI 0.04--2.55, respectively).Fig. 5Forest plot and meta-analysis of procedure-related mortality rate: giant aneurysms vs. small/large aneurysms. *M-H* Mantel-Haenszel method, *CI* confidence intervalFig. 6Forest plot and meta-analysis of procedure-related mortality rate: basilar artery aneurysms vs. non basilar artery aneurysms. *M-H* Mantel-Haenszel method, *CI* confidence interval

The rate of aneurysm complete occlusion at 6-month DSA was 84 % (95 % CI 68--94), with no significant association with aneurysm size (OR 3.60, 95 % CI 0.26--50.84). Ischemic stroke rate was 11 % (95 % CI 7--17) with no significant association with aneurysm size (OR 1.06, 95 % CI 0.26--4.30). Perforator infarction rate was 7 % (95 % CI 3--13). Postoperative SAH was 3 % (95 % CI 1--6 %). IPH rate was 4 % (95 % CI 1--8). The above data are summarized in Table [3](#Tab3){ref-type="table"}.Table 3Outcomes for endovascular treatment of posterior circulation aneurysms with FDsOutcomeRate (95 % CI)OR95 % CI*I* ^2^ (%)Procedure-related mortality (mRS 6)0.15 (0.10--0.21) Aneurysm size (giant vs. small/large)^a^Giant0.37 (0.22--0.54)3.771.35--10.540Small/large0.08 (0.04--0.15) Aneurysm type (saccular vs. not saccular)Saccular0 (0--0.12)0.150.02--1.130Not saccular0.18 (0.10--0.28) Aneurysm location (basilar artery vs. not basilar artery)^a^Basilar artery0.25 (0.14--0.37)4.651.24--17.400Not basilar artery0.07 (0.02--0.18) Aneurysm state (rupture vs. unrupture)Rupture0.14 (0.03--0.36)1.960.28--13.620Unrupture0.11 (0.05--0.20) Preoperative symptoms (with vs. without)With0.18 (0.10--0.30)2.170.17--27.910Without0 (0--0.10) Prior treatment (retreatment vs. first treatment)Retreatment0 (0--0.14)0.330.04--2.550First treatment0.16 (0.08--0.26)Procedure-related good outcome (mRS 0--2)0.79 (0.72--0.84) Aneurysm size (small vs. large/giant)Small0.73 (0.57--0.86)0.990.37--2.6611Large/giant0.70 (0.60--0.79) Aneurysm type (saccular vs. not saccular)Saccular1 (0.83--1)6.20.69--55.550Not saccular0.70 (0.57--0.81) Aneurysm location (basilar artery vs. not basilar artery)^a^Basilar artery0.55 (0.41--0.69)0.140.04--0.540Not basilar artery0.95 (0.83--0.99) Aneurysm state (rupture vs. unrupture)^a^Rupture0.68 (0.46--0.85)0.220.06--0.820Unrupture0.82 (0.74--0.88) Preoperative symptoms (with vs. without)With0.65 (0.52--0.77)0.20.04--1.070Without0.97 (0.85--1) Prior treatment (retreatment vs. first treatment)Retreatment0.92 (0.73--0.99)1.720.40--7.340First treatment0.73 (0.61--0.83)Complete occlusion rate at 6-month DSA0.84 (0.68--0.94) Aneurysm size (small vs. large/giant)Small1 (0.40--1)3.60.26--50.840Large/giant0.6 (0.15--0.95)Ischemic stroke0.11 (0.07--0.17) Aneurysm size (small vs. large/giant)Small0.13 (0.04--0.29)1.060.26--4.300Large/giant0.14 (0.07--0.24)Perforator infarction0.07 (0.03--0.13)Subarachnoid hemorrhage0.03 (0.01--0.06)Intraparenchymal hemorrhage0.04 (0.01--0.08)*CI* confidence interval, *mRS* modified Rankin scale, *DSA* digital subtraction angiography, *OR* odds ratio^a^Denotes statistically significant results

Sensitivity analysis and publication bias {#Sec7}
-----------------------------------------

None of the analyses conducted exhibited heterogeneity except for the analysis of procedure-related good outcome with different size aneurysms (*I*^2^ = 11 %), suggesting unexplained minimal differences in study populations and procedures. Funnel plot analyses on the statistically significant studies are shown in Figs. [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, and [10](#Fig10){ref-type="fig"}, which indicated significant publication bias.Fig. 7Procedure-related good outcome rate: ruptured aneurysms vs. unruptured aneurysms. *SE* standard error, *OR* odds ratioFig. 8Procedure-related good outcome rate: basilar artery aneurysms vs. non basilar artery aneurysms. *SE* standard error, *OR* odds ratioFig. 9Procedure-related mortality rate: giant aneurysms vs. small/large aneurysms. *SE* standard error, *OR* odds ratioFig. 10Procedure-related mortality rate: basilar artery aneurysms vs. non basilar artery aneurysms. *SE* standard error, *OR* odds ratio

Discussion {#Sec8}
==========

With recent advancements in neuroendovascular technology, flow-diverting stents provided a new therapeutic option of total intraluminal reconstruction for the treatment of intracranial aneurysm. But compared with traditional clipping and coiling, the use of FDs was restricted to giant and complex aneurysms. Our meta-analysis included 225 aneurysms. Large or giant aneurysms accounted for 71 % of the total, and 66 % of the aneurysms were classified as not saccular aneurysms, including fusiform, dissecting, blister, and other complex aneurysms. Similar to conventional stents, flow-diverting stents have also been controversial in the treatment of ruptured aneurysms because of the necessity of antiaggregation pre- and post-operation. Of the 225 aneurysms reported here, 84 % were unruptured. For ruptured aneurysms, there is still no evidence-based concept or large agreement on antiplatelet and anticoagulation schedule. Stephan et al. \[[@CR7]\] gave patients with ruptured aneurysms an intravenous bolus of heparin (5000 IU) and aspirin (500 mg) at the start of the procedure. After the procedure, intravenous heparin continued for 2 days; double antiplatelet therapy with clopidogrel (75--150 mg/day) and aspirin (81--325 mg/day) was continued for variable duration. However, in other clinical centers, patients received a loading dose of only 300 mg clopidogrel and 300 mg aspirin 6 h before aneurysm treatment \[[@CR9]\], a loading dose of clopidogrel 600 mg and aspirin 325 mg the night before surgery \[[@CR13]\], or 300/600 mg of clopidogrel on the day of the procedure \[[@CR2]\].

In our meta-analysis, 79 % of the patients showed a good outcome. The rates ranged from 29 to 100 % \[[@CR1], [@CR2], [@CR6]--[@CR15]\], highlighted by significantly lower rates in the patients with ruptured and basilar artery aneurysms. Meanwhile, patients with basilar artery aneurysms had a higher mortality rate. The basilar artery is rich of perforator arteries, most of which supply the cerebellum, brain stem, and other important structures. What is worse, these areas lack effective vascular compensatory mechanisms. As a consequence, a relatively higher perforator infarction rate was observed when FDs were placed in the vascular lumen. The association between the location of the aneurysms and the rate of perforator infarction during the follow-up was not analyzed in our meta-analysis because of a lack of information in many studies, but studies reporting the perforator infarction of basilar artery reported relatively higher rates from 14 to 25 % \[[@CR2], [@CR7]--[@CR9]\]. These results may account for adverse outcomes in patients with basilar artery aneurysms. Patients with ruptured aneurysms had worse preoperative status compared to those with unruptured aneurysms. These factors likely lead to a lower good outcome rate, but not to a higher mortality rate.

Mortality rate was another important indicator for evaluating the safety of flow diverter treatment for patients with PCAs. Published mortality rates were variable, ranging from 0 to 57 % \[[@CR1], [@CR2], [@CR5]--[@CR15]\]. Our meta-analysis provided more representative data on mortality rate, with significantly higher rates among patients with giant and basilar artery aneurysms. What accompanying with giant aneurysms are always rupture, preoperative symptoms, higher rates of ischemic stroke, and postoperative SAH \[[@CR4]\]; none of which are conducive to the recovery of patients. However, patients with ruptured aneurysms or preoperative symptoms did not have a higher mortality rate than patients without. In the meta-analysis reported by Brinjikji et al. \[[@CR4]\], 1451 patients with 1654 intracranial aneurysms were treated with FDs, and the total mortality rate was 4 %, which was significantly lower than that in the patients with PCAs reported here.

The target of endovascular treatment is to prevent aneurysms from either the first or a repeated rupture, so the occlusion rate is the most important indicator to measure the effectiveness of flow diverter treatment. We found a complete occlusion rate of more than 80 % at 6-month DSA, which compared favorably with that of stent-assisted \[[@CR17]\] or balloon-assisted embolization \[[@CR18]\].

The main complications of FDs are ischemic stroke, perforator infarction, postoperative SAH, and IPH. They were not rare in our meta-analysis, as only one study definitively reported none of these complications \[[@CR3]\]. Ischemic stroke was the most common complication, followed by perforator infarction and IPH, and postoperative SAH. Among these complications, the rates of ischemic stroke and perforator infarction were apparently higher than those reported for flow diverter treatment of intracranial aneurysms, which were 6 and 3 % respectively \[[@CR4]\]. High ischemic complications may relate with the lack of optimal platelet inhibition, so platelet function tests should be performed on all patients prior to the procedure to make sure that the level of platelet inhibition was adequate (\>30 %) \[[@CR3], [@CR8]\]. What is more, adverse event rates drop significantly with experience. Brinjikji et al. \[[@CR4]\] reported a significantly higher rate of ischemic stroke among patients with large/giant aneurysms, and ascribed the cause to the longer operation time. We also analyzed the association between the ischemic stroke rate and the size of the aneurysms, but did not find similar results. This may be partly due to the small number of cases analyzed.

Several limitations might have affected our results. Publication bias is the most common systematic error of meta-analysis, and it should be carefully considered here because our results were based mostly on small studies. Compared with large studies, small studies have reported more adverse outcomes, and studies describing only a small number of patients may be more easily accepted for publication if they alert for any adverse events \[[@CR16]\]. Secondly, the available studies were of poor quality, as approximately half were retrospective case series. Thirdly, because studies with significant results are more likely to be published in English, we only included English language articles. As a consequence, it is possible that some high quality studies in other languages might have been excluded. Finally, the standard of selecting patients, pre- and post-procedural antiplatelet/anticoagulation protocol, the number and kind of the stents used, and personal experience with stenting techniques varied in studies.

Conclusions {#Sec9}
===========

Flow diverter treatment of PCAs is an effective method which provides a high rate of complete occlusion at 6-month DSA. But compared with treatment of anterior circulation aneurysms, it has significantly higher rates of mortality, ischemic stroke and perforator infarction. Our findings indicate that, in most clinical centers, flow diverter treatment of PCAs should be conducted in carefully selected patients with poor natural history and no optimal treatment strategy. For ruptured and giant basilar artery aneurysms, there is still no good treatment option, and the problem is unsolved. The findings reported herein suggest that further well-designed prospective large studies are needed.
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